Effect of anti-TNF-alpha treatment in an antibiotic treated murine model of shock due to Streptococcus pyogenes.
Experimentally, Gram-negative septic shock can be prevented by the prophylactic use of an anti-TNF-alpha monoclonal antibody. The clinical similarity between Gram-negative and Gram-positive septic shock suggested that anti-TNF-alpha therapy might have a wide application. Increased levels of TNF-alpha were seen in a murine model of septic shock due to Streptococcus pyogenes but administration of an anti-TNF-alpha monoclonal antibody had no beneficial effect on the outcome.
Martin
R A
RA
Department of Infectious Diseases and Bacteriology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Silva
A T
AT
Cohen
J
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002981:Clindamycin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004353:Drug Evaluation, Preclinical; D007167:Immunotherapy; D008297:Male; D051379:Mice; D012772:Shock, Septic / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy*; D013290:Streptococcal Infections / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy*; D013297:Streptococcus pyogenes; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D002981:Clindamycin